This article is more than 5 years old. Information may no longer be current.
Coming soon from San Francisco: Breaking news from ACC Scientific Sessions
Click Here to Manage Email Alerts
Beginning on Saturday, March 9, the Cardiology Today and Healio.com/Cardiology team will present live coverage from the American College of Cardiology’s 62nd Annual Scientific Sessions and TCT@ACC-i2.
The conference will feature 3 days of scientific sessions, including 22 late-breaking clinical trial presentations, 2,130 accepted abstracts, consumer research and more.
The late-breaking trials will feature results from:
- PREVAIL, an analysis of left atrial appendage closure vs. warfarin for the prevention of stroke/thromboembolism in patients with nonvalvular atrial fibrillation.
- HPS2-THRIVE, a study of extended-release niacin/laropiprant vs. placebo in more than 25,000 patients at high risk for occlusive vascular events.
- RELAX, an evaluation of phosphodiesterase-5 inhibition on clinical status and exercise capacity in patients with diastolic HF.
Speaking at a telebriefing, ACC president William Zoghbi, MD, FACC, said, “For PREVAIL, there are huge numbers of patients suffering from AF in an age group where the risk of anticoagulation starts becoming a real problem vs. a benefit because of bleeding issues. If in fact this trial does show positive results, the impact could be quite striking.”
William Zoghbi
“RELAX, on the other hand, could be very important because diastolic HF is still treated in the same way that it was 15 years ago. If this new agent came out with a striking result it could very well be revolutionary," Zoghbi said.
Data from CHAMPION PHEONIX, TERISA, ASTRONAUT and REMINDER late-breaking trials will also be presented, among others.
Other sessions will focus on research highlighting how a major community crisis can affect CV health, including research from New Orleans and the continuing impact of Hurricane Katrina and research from Greece on the effects of the financial crisis.
One featured research session will include data from an examination of atherosclerosis over 3,800 years of human history. More than 100 mummies from different areas of the world were examined by CT scan to determine the presence of atherosclerosis. "This is going to be a very exciting presentation because it's going to give us a snapshot look at a population that lived [almost] 400,000 years ago that probably had a different lifestyle from what we have today to see whether they suffered or didn't suffer from atherosclerosis," ACC chair Miguel Quinones, MD, MACC, said during the press briefing.
The conference is from March 9 to 11. Visit Healio.com/Cardiology to read about these results and more.
Disclosure: Quinones reports no relevant financial disclosures. Zoghbi reports a licensing agreement with GE Healthcare.